| 2025 |
Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340.
DOI Europe PMC1 |
| 2024 |
Li, M., Bennett, M. K., Toubia, J., Pope, V. S., Tea, M. N., Tamang, S., . . . Pitson, S. M. (2024). An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma. British Journal of Haematology, 204(2), 566-570.
DOI Scopus1 WoS1 Europe PMC1 |
| 2024 |
Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20.
DOI Scopus10 WoS11 Europe PMC7 |
| 2022 |
Lewis, A. C., Pope, V. S., Tea, M. N., Li, M., Nwosu, G. O., Nguyen, T. M., . . . Pitson, S. M. (2022). Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.. Blood, 139(26), 3737-3751.
DOI Scopus37 WoS32 Europe PMC35 |
| 2022 |
Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., . . . Gargett, T. (2022). Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. Frontiers in immunology, 13, 850226-1-850226-19.
DOI Scopus23 WoS21 Europe PMC18 |
| 2022 |
Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
DOI Scopus79 WoS79 Europe PMC75 |
| 2021 |
Oksdath Mansilla, M., Salazar-Hernandez, C., Perrin, S. L., Scheer, K. G., Cildir, G., Toubia, J., . . . Gomez, G. A. (2021). 3D-printed microplate inserts for long term high-resolution imaging of live brain organoids. BMC biomedical engineering, 3(6), 1-14.
DOI Europe PMC17 |
| 2021 |
Lenin, S., Ponthier, E., Scheer, K. G., Yeo, E. C. F., Tea, M. N., Ebert, L. M., . . . Gomez, G. A. (2021). A drug screening pipeline using 2D and 3D patient-derived in vitro models for pre-clinical analysis of therapy response in glioblastoma. International Journal of Molecular Sciences, 22(9), 4322-1-4322-27.
DOI Scopus38 WoS37 Europe PMC35 |
| 2021 |
Bennett, M. K., Li, M., Tea, M. N., Pitman, M. R., Toubia, J., Wang, P. P. -S., . . . Pitson, S. M. (2021). Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.. Neoplasia, 24(1), 1-11.
DOI Scopus16 WoS16 Europe PMC13 |
| 2020 |
Tea, M. N., Poonnoose, S. I., & Pitson, S. M. (2020). Targeting the sphingolipid system as a therapeutic direction for glioblastoma. Cancers, 12(1), 111-1-111-25.
DOI Scopus41 WoS40 Europe PMC35 |
| 2020 |
Boyle, S. T., Poltavets, V., Kular, J., Pyne, N. T., Sandow, J. J., Lewis, A. C., . . . Samuel, M. S. (2020). ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism. Nature Cell Biology, 22(7), 882-895.
DOI Scopus60 WoS60 Europe PMC56 |
| 2020 |
Boyle, S. T., Poltavets, V., Kular, J., Pyne, N. T., Sandow, J. J., Lewis, A. C., . . . Samuel, M. S. (2020). Publisher Correction: ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.. Nat Cell Biol, 22(7), 908.
DOI Scopus5 WoS4 Europe PMC6 |
| 2020 |
Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24.
DOI Scopus51 WoS48 Europe PMC47 |
| 2019 |
Neubauer, H. A., Tea, M. N., Zebol, J. R., Gliddon, B. L., Stefanidis, C., Moretti, P. A. B., . . . Pitson, S. M. (2019). Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. Oncogene, 38(8), 1151-1165.
DOI Scopus26 WoS24 Europe PMC18 |
| 2017 |
Hughes, J., Dawson, R., Tea, M., McAninch, D., Piltz, S., Jackson, D., . . . Thomas, P. (2017). Knockout of the epilepsy gene Depdc5 in mice causes severe embryonic dysmorphology with hyperactivity of mTORC1 signalling. Scientific Reports, 7(1), 12618-1-12618-15.
DOI Scopus51 WoS47 Europe PMC45 |
| 2013 |
Tea, M., Michael, M. Z., Brereton, H. M., & Williams, K. A. (2013). Stability of small non-coding RNA reference gene expression in the rat retina during exposure to cyclic hyperoxia. Molecular vision, 19, 501-508. |
| 2012 |
Colella, A., Chegenii, N., Tea, M. N., Gibbins, I., Williams, K., & Chataway, T. (2012). Comparison of Stain-Free gels with traditional immunoblot loading control methodology. Analytical biochemistry, 430(2), 108-110.
DOI |
| 2009 |
Tea, M., Fogarty, R., Brereton, H., Michael, M., Van der Hoek, M., Tsykin, A., . . . Williams, K. (2009). Gene expression microarray analysis of early oxygen-induced retinopathy in the rat. Journal of Ocular Biology, Diseases, and Informatics, 2(4), 190-201.
DOI Scopus14 Europe PMC10 |
| 2008 |
Irani, Y., Tea, M. N., Tilton, R. G., Coster, D., Williams, K., & Brereton, H. (2008). PCR amplification of the functional immunoglobulin heavy chain variable gene from a hybridoma in the presence of two aberrant transcripts. Journal of Immunological Methods, 336(2), 246-250.
DOI Scopus12 WoS12 Europe PMC9 |
